Literature DB >> 11355896

Rapamycin blocks IL-2-driven T cell cycle progression while preserving T cell survival.

J Gonzalez1, T Harris, G Childs, M B Prystowsky.   

Abstract

Effective cellular immune responses require increases in antigen-specific T lymphocytes; IL-2 drives antigen-stimulated T cell proliferation and is largely responsible for the increases observed. We used microarrays containing approximately 9000 mouse cDNAs to study IL-2-induced gene expression. IL-2 induces the expression of genes that regulate cell cycle progression, control cell survival, and increase synthetic and metabolic processes during proliferation. IL-2 also suppresses expression of genes that block cell cycle progression and promote cell death. Rapamycin inhibits IL-2-driven proliferation by downregulating the expression of genes required for key processes required for cell cycle progression. Rapamycin also preserves cell survival by keeping intact the IL-2-induced cell survival programs. These complex multifaceted programs of gene expression permit a dynamic regulation of cellular proliferation and cellular survival. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11355896     DOI: 10.1006/bcmd.2001.0420

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  7 in total

1.  Defects in skin gamma delta T cell function contribute to delayed wound repair in rapamycin-treated mice.

Authors:  Robyn E Mills; Kristen R Taylor; Katie Podshivalova; Dianne B McKay; Julie M Jameson
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

2.  Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation.

Authors:  Stephanie Oliere; Meztli Arguello; Thibault Mesplede; Vanessa Tumilasci; Peyman Nakhaei; David Stojdl; Nahum Sonenberg; John Bell; John Hiscott
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

Review 3.  Synthesis and biological evaluation of rapamycin-derived, next generation small molecules.

Authors:  Shiva Krishna Reddy Guduru; Prabhat Arya
Journal:  Medchemcomm       Date:  2017-11-22       Impact factor: 3.597

4.  DNA array analysis of interleukin-2-regulated immediate/early genes.

Authors:  Carol Beadling; Kendall A Smith
Journal:  Med Immunol       Date:  2002-11-18

5.  Dysfunction of the mTOR pathway is a risk factor for Alzheimer's disease.

Authors:  Sharon C Yates; Amen Zafar; Paul Hubbard; Sheila Nagy; Sarah Durant; Roy Bicknell; Gordon Wilcock; Sharon Christie; Margaret M Esiri; A David Smith; Zsuzsanna Nagy
Journal:  Acta Neuropathol Commun       Date:  2013-05-08       Impact factor: 7.801

6.  Molecular characterization of breast cancer cell response to metabolic drugs.

Authors:  Lucía Trilla-Fuertes; Angelo Gámez-Pozo; Jorge M Arevalillo; Mariana Díaz-Almirón; Guillermo Prado-Vázquez; Andrea Zapater-Moros; Hilario Navarro; Rosa Aras-López; Irene Dapía; Rocío López-Vacas; Paolo Nanni; Sara Llorente-Armijo; Pedro Arias; Alberto M Borobia; Paloma Maín; Jaime Feliú; Enrique Espinosa; Juan Ángel Fresno Vara
Journal:  Oncotarget       Date:  2018-01-08

Review 7.  HIV-Related Immune Activation and Inflammation: Current Understanding and Strategies.

Authors:  Tingxia Lv; Wei Cao; Taisheng Li
Journal:  J Immunol Res       Date:  2021-09-29       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.